



**Raban V Jeger**

**Contact**

Raban V Jeger

## Publications (16)

Mahendiran T, Hoepfl A, Foster-Witassek F, Rickli H, Roffi M, Eberli F, Pedrazzini G, Jeger R, Radovanovic D, Fournier S, AMIS Plus Investigators. Twenty-year trends in the prevalence of modifiable cardiovascular risk factors in young acute coronary syndrome patients hospitalized in Switzerland. *Eur J Prev Cardiol* 2023; 30:1504-1512.

Stauber A, Mueller A, Rommers N, Aeschbacher S, Rodondi N, Bonati L, Beer J, Jeger R, Kurz D, Liedtke C, Ammann P, Di Valentino M, Chocano-Bedoya P, Kobza R, Kühne M, Conen D, Osswald S, Bernheim A. Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF). *Swiss Med Wkly* 2023; 153:40109.

Rubini Gimenez M, Scheller B, Farah A, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Cuculi F, Leibundgut G, Möbius-Winkler S, Cattaneo M, Gilgen N, Kaiser C, Jeger R. Sex-specific inequalities in the use of drug-coated balloons for small coronary artery disease: a report from the BASKET-SMALL 2 trial. *Clin Res Cardiol* 2023

Seeger J, Wöhrle J, Scheller B, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Weilenmann D, Stachel G, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Jeger R, On Behalf Of The Basket-Small Investigators. Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial. *J Cardiovasc Dev Dis* 2023; 10

Biasco L, Foster-Witassek F, Radovanovic D, Dittli P, Tersalvi G, Rickli H, Roffi M, Eberli F, Jeger R, Erne P, Pedrazzini G. Prognostic value of low heart rates in patients admitted with acute myocardial infarction. *Rev Esp Cardiol (Engl Ed)* 2023; 76:626-634.

Scheller B, Rissanen T, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Coslovsky M, Mahfoud F, Jeger R, BASKET-SMALL 2 Investigators. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. *Circ Cardiovasc Interv* 2022; 15:e011569.

Mahfoud F, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Kaiser C, Cattaneo M, Scheller B, Jeger R. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. *Clin Res Cardiol* 2022; 111:806-815.

Mangner N, Farah A, Ohlow M, Möbius-Winkler S, Weilenmann D, Wöhrle J, Linke A, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Scheller B, Jeger R, BASKET-SMALL 2 Investigators. Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. *Circ Cardiovasc Interv* 2022; 15:e011325.

Wöhrle J, Jeger R, Kaiser C, Gilgen N, Cattaneo M, Rickenbacher P, Leibundgut G, Stachel G, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, Seeger J, Scheller B, BASKET-SMALL 2 Investigators. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial. *JACC Cardiovasc Interv* 2021; 14:1789-1798.

Jeger R, Scheller B, Kaiser C, Gilgen N, Cattaneo M, Osswald S, Rickenbacher P, Leibundgut G, Markovic S, Stachel G, Wöhrle J, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. *Lancet* 2020; 396:1504-1510.

Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliminet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PloS one* 2019; 14:e0210821.

Jeger R, Stephan F, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B, Linke A, Mahfoud F, Schreiber M, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *Lancet* 2018; 392:849-856.

Jeger R, Erne P, Nossen J, Stauffer J, Pedrazzini G, Urban P, Rickli H, Eberli F, Radovanovic D, Pfister O, AMIS-Plus Investigators. Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry. *Clin Cardiol* 2017; 40:907-913.

Jeger R, Kaiser C, Galatius S, Rickli H, Pedrazzini G, Erne P, Eberli F, Bonetti P, Alber H, von Felten S, Sørensen R, Pfisterer M, BASKET and BASKET-PROVE investigators. Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. *Am Heart J* 2014; 168:698-705.

Jeger R, Seeberger M, Keller U, Pfisterer M, Filipovic M. Oral hypoglycemics: increased postoperative mortality in coronary risk patients. *Cardiology* 2007; 107:296-301.

Jeger R, Probst C, Arsenic R, Lippuner T, Pfisterer M, Seeberger M, Filipovic M. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. *American heart journal* 2006; 151:508-13.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)